Thymosin Beta-4 (17-23)
The 17-23 fragment of thymosin beta-4 (LKKTETQ) is the minimal active sequence responsible for actin-binding and tissue remodeling activity of the full TB-500 molecule.
Protocol
500 mcg–1 mg, 2–3x weekly
Half-Life
3–5 hours
Molecular Structure & Chemistry
20 residues • 331 atoms • Skeletal Formula
C116H157N27O29S2
2,097.52 g/mol
2456.109 Da
5.29
-1.03
-0.2
Amino Acid Sequence
Biological Mechanisms
Promotes actin polymerization
Observed in clinical research as a primary mechanism of action for Thymosin Beta-4 (17-23).
Connective tissue repair
Observed in clinical research as a primary mechanism of action for Thymosin Beta-4 (17-23).
Anti-inflammatory
Observed in clinical research as a primary mechanism of action for Thymosin Beta-4 (17-23).
Faster recovery
Observed in clinical research as a primary mechanism of action for Thymosin Beta-4 (17-23).
Wound healing
Observed in clinical research as a primary mechanism of action for Thymosin Beta-4 (17-23).
Safety & Risk Analysis
Critical Safety Warning
Black market peptides can be contaminated, mislabeled, or dangerous. Only obtain peptides via a registered doctor and legitimate pharmacy. Never attempt self-administration without professional medical supervision.
Community Journey Log
Log Your Journey
Share your research observations with the community.
Sign in to contribute
Create a free account to log your research journey and share observations with the community.
Community Observations (0)
No journey logs yet. Be the first to share.
This compound is for research purposes only. Clinical applications must be directed by a licensed physician.
View Community Logs